MarketCatalyst
← Back to Research
Earnings

Keel Infrastructure Q3 2026 Revenue Tops Estimates at $27.6M, but EPS Misses at -$0.10

Revenue of $27.6M vs. $18.7M expected and adjusted EPS of -$0.10 vs. -$0.09; revenue down 60% from a year earlier.

Published Nov 5, 2026 · 7:02 AM ET · 2 min read

Keel Infrastructure (KEEL) posted mixed third-quarter 2026 results, with revenue above the estimate and adjusted EPS below it. Revenue was $27.6 million, down 60% from a year earlier, above the $18.7 million estimate, and adjusted EPS was -$0.10, down 25% from a year earlier, below the -$0.09 estimate.

Shares rose 0.2% in premarket trading as of 7:02 a.m. ET, to $2.12 from a $2.12 close.

-$0.10
Adjusted EPS, down 25% YoY vs. -$0.09 estimate
$27.6M
Revenue, down 60% YoY vs. $18.7M estimate
+0.2%
Shares premarket as of 7:02 a.m. ET

Q3 2026 scorecard

ParametersExpectedActualBeat/Miss
Adjusted EPS-$0.09-$0.10Miss by 13%
Revenue$18.7M$27.6MBeat by 47%
ChangeYoYQoQ
Adjusted EPS▼ 25%▲ 9.1%
Revenue▼ 60%▼ 9.3%

By our calculation, revenue was $8.9 million above the estimate and adjusted EPS was $0.01 below it. The QoQ column compares with the previous quarter's revenue of $30.4 million and adjusted EPS of -$0.11. The YoY column compares with $69.2 million and -$0.08 in the same quarter a year earlier.

Track record

  • EPS record. Adjusted EPS beat the estimate in 1 of the last 8 reports, including this one.
  • Revenue record. Revenue beat the estimate in 3 of the last 8 reports.
  • Revenue trend. Revenue over the last 5 reports, oldest first: $69.2 million, $52.4 million, $37.0 million, $30.4 million and $27.6 million.

What to watch

  • Next-quarter estimates. Consensus calls for EPS of -$0.09 and revenue of $17.3 million next quarter, based on 4 analysts.
  • Revenue growth. Whether revenue stabilizes after this quarter's 60% decline from a year earlier to $27.6 million.
  • Estimate record. Whether Keel Infrastructure returns to beating EPS estimates, which it did in 1 of its last 8 reports.
  • Related coverage. See our reports on Iovance Biotherapeutics, Axcelis, GPGI and Certara.

Sources: Results are from Keel Infrastructure's Nov. 5, 2026 quarterly report. Estimates are consensus figures. The prior-quarter and year-ago comparison figures are from Keel Infrastructure's earlier quarterly reports. Items labeled by our calculation are our own arithmetic. This article is informational only and is not investment advice.

Readers also read

MarketCatalyst is not a registered investment advisor and does not manage client assets. Content on this platform is provided for informational and educational purposes only. It is not investment advice, and MarketCatalyst is not a stock-picking or trade-alert service. Trading stocks and options involves risk, including the possible loss of principal. Consider your own goals, time horizon, and risk tolerance, and consult a qualified financial advisor before making any investment decision.

Keel Infrastructure Q3 2026 Revenue Tops Estimates